Risk stratification for sudden cardiac death in postinfarct patients and in patients with dilated cardiomyopathy [Risikostratifikation für den plötzlichen herztod bei postinfarktpatienten und bei patienten mit dilatativer kardiomyopathie]

被引：0
作者：
Grimm W. [1 ]
机构：
[1] Philipps-Universität Marburg, Zentrum fur Innere Med. - Kardiol., 35033 Marburg, Baldingerstr.
来源：
Zeitschrift für Kardiologie | 2000年 / 89卷 / Suppl 10期
关键词：
Implantable cardioverter defibrillator; Risk stratification; Sudden cardiac death;
D O I：
10.1007/s003920070003
中图分类号：
学科分类号：
摘要：
In patients with structural heart disease and sustained symptomatic ventricular tachycardia or ventricular fibrillation without reversible cause, the implantable cardioverterdefibrillator has become the therapy of first choice. Besides the "MADIT indication", however, arrhythmia risk stratification with regard to prophylactic ICD implantation is an unsolved problem. This overview summarizes the currently very limited clinical value of potential risk predictors for sudden cardiac death in postinfarct patients and in patients with dilated cardiomyopathy.
引用
收藏
页码：11 / 20
页数：9
相关论文
共 47 条
[1]  
A Comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias, N Engl J Med, 337, pp. 1576-1583, (1997)
[2]  
Gregoratos G., Cheitlin M.D., Conill A., Et al., ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the ACC/AHA Task Force on Practice Guidelines (Committee on Pacemaker Implantation), J Am Coll Cardiol, 31, pp. 1175-1206, (1998)
[3]  
Moss A.J., Hall J., Cannom D.S., Et al., Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia, N Engl J Med, 335, pp. 1933-1940, (1996)
[4]  
Lee K.L., Buxton A.E., Hafley G.E., Fisher J.D., Prystowski E.N., Josephson M.E., EP-guided therapy reduces the risk of arrhythmic events due to the use of ICDs, but not antiarrhythmic drugs: Results from MUSTT, Circulation, 100, SUPPL. I, (1999)
[5]  
Bigger J.T. Jr., Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery, N Engl J Med, 337, pp. 1569-1575, (1997)
[6]  
Effect of Encainide and Flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, N Engl J Med, 321, pp. 406-412, (1989)
[7]  
Waldo A.L., Camm A.J., DeRuyter H., Et al., Effect of D-Sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction, Lancet, 348, pp. 7-12, (1996)
[8]  
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure, Lancet, 350, pp. 1417-1424, (1997)
[9]  
Effect of metoproiol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF), Lancet, 353, pp. 2001-2007, (1999)
[10]  
Moss A.J., Cannom D.S., Daubert J.P., Et al., Multicenter Automaitc Defibrillator Implantation Trial II (MADIT II): Design and clinical protocol, Ann Noninvasive Electrocardiol, 4, pp. 83-91, (1999)
12345